A Phase 3 interventional study of Mitiglinide in Diabetes, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed. Open to participants aged 25 Years to 70 Years. Per ClinicalTrials.gov, last updated 2008-10-21.
Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the efficacy and safety of Mitiglinide compared to Nateglinide for the treatment of type 2 diabetes.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
This study's enrollment of 291 is above the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Kissei Pharmaceutical Co., Ltd. is the lead sponsor of 63 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Nateglinide 120 mg TID
Drug: Mitiglinide
10mg tablet, 10mg TID
Also known as: Glufast
Hemoglobin A1C (HbA1C)
Time frame: -2, 0, 4, 8, 10, 12, 16, 20 week
Fasting plasma glucose level (FPG)
Time frame: 0, 4, 8, 12, 16, 20 week
Two-hour postprandial glucose level (PPG2)
Time frame: 0, 12, 20 week
One-hour postprandial glucose level (PPG1)
Time frame: 0, 12, 20 week
No study locations are listed for this record.
The record gives a start of Aug 2006, a primary completion of Jul 2007 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mitiglinide
Kissei Pharmaceutical Co., Ltd. →